First-in-Human Trial of CAR-γδT Cells Shows Promise for Patients With Recurrent Glioblastoma: ESMO 2024
A groundbreaking clinical trial testing QH104, an allogeneic B7H3-targeting CAR-γδT cell therapy, has shown promising results for patients with recurrent glioblastoma.